Opdivo (Yervoy) (nivolumab (ipilimumab))

pCPA File Number: 21427
Negotiation Status:
Under consideration for negotiation
Indication(s):
First-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC)
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CADTH Project Number:
PC0218-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable